Pharmesis International Ltd. (SGX:BFK)

Pharmesis International Revenue

Pharmesis International had revenue of 11.87M CNY in the half year ending June 30, 2026, a decrease of -50.30%. This brings the company's total for the last twelve months to 28.42M, down -59.97% year-over-year. In the year 2025, Pharmesis International had annual revenue of 43.75M, down -35.32%. That makes Pharmesis International the 40,478th largest company in the world by revenue and 480th in Singapore.

• Revenue (ttm): 28.42M CNY
• Revenue Growth: -59.97%
• P/S Ratio: 0.56
• Revenue / Employee: 25.93K CNY
• Employees: 1,096
• Market Cap: 3.01M SGD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Segment

Chart

• Distribution 26.54M 38.5%
• TCM Formulated Drugs/IP Rental 26.05M 37.7%
• Western Drugs / TCH Procurement 16.43M 23.8%

Fiscal year ended Dec 31, 2025 See the full Pharmesis International breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	43.75M	-23.90M	-35.32%
Dec 31, 2024	67.65M	22.01M	48.24%
Dec 31, 2023	45.64M	-4.73M	-9.40%
Dec 31, 2022	50.37M	-2.40M	-4.55%
Dec 31, 2021	52.77M	5.66M	12.01%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 22, 2026

Data Sources Report a data error